modotuximab
Term · Oncology and biomedicine · MLC-T-ONC-015232
A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibition EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, often is overexpressed on the cell surfaces of various solid tumor cell types.
| Identifier | MLC-T-ONC-015232 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | zatuximab |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015232",
"term": "modotuximab",
"field": "Oncology and biomedicine",
"definition": "A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibition EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, often is overexpressed on the cell surfaces of various solid tumor cell types.",
"synonyms": [
"zatuximab"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/modotuximab/"
}
Record 11,179 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.